In a report released today, Ed Arce from H.C. Wainwright maintained Pliant Therapeutics (PLRX – Research Report) to a Buy, with a price target of $52.00. Ed Arce’s Buy rating for Pliant Therapeutics ...
Investing.com -- Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) tumbled 64% following the company's announcement to halt enrollment and dosing in its Phase 2b trial of bexotegrast for idiopathic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results